Trial Profile

An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Piclidenoson (Primary)
Indications Oculocerebrorenal syndrome
Focus Therapeutic Use
Acronyms PICLILOWE
Sponsors Can-Fite BioPharma

Most Recent Events

03 Aug 2026 According to a Can-Fite BioPharma media release, the company submitted a Phase II clinical study protocol to Bambino Gesu Children's Hospital in Rome, Italy, for the first clinical evaluation of Piclidenoson in patients with Lowe syndrome.
13 Feb 2026 Status changed from planning to not yet recruiting.
16 Dec 2025 According to a Can-Fite BioPharma media release, company has completed a phase II study protocol for rare genetic disease Lowe Syndrome and plans to submit it to Italian and EMA authorities in Q1 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com